0001415889-24-001754.txt : 20240124 0001415889-24-001754.hdr.sgml : 20240124 20240124163941 ACCESSION NUMBER: 0001415889-24-001754 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240122 FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Macrae Sandy CENTRAL INDEX KEY: 0001675687 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 24556969 MAIL ADDRESS: STREET 1: 721 ST. GEORGES ROAD CITY: PHILADELPHIA STATE: PA ZIP: 19119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD. CITY: RICHMOND STATE: CA ZIP: 94084 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD. CITY: RICHMOND STATE: CA ZIP: 94084 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 form4-01242024_090135.xml X0508 4 2024-01-22 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001675687 Macrae Sandy C/O SANGAMO THERAPEUTICS, INC. 501 CANAL BLVD. RICHMOND CA 94084 true true false false PRESIDENT, CEO AND DIRECTOR 0 Common Stock 2024-01-22 4 A 0 2000000 0 A 2592476 D Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration in full in the event of a Change in Control (as defined in the 2018 EIP). Includes: (a) 46,134 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (b) 105,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (c) 157,300 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. /s/ Ron A. Metzger, Attorney-in-Fact 2024-01-24